A new global consensus published in Hepatology recommends a common approach to diagnosing and managing acute-on-chronic liver failure (ACLF), including updated diagnostic criteria, a three-level severity grading system, and expedited transplant evaluation for severe disease. The recommendations aim to guide treatment decisions and improve consistency in research across regions. Additionally, GI & Hepatology News associate editor Brian Kim, MD, FACG, FAASLD, has published commentary on the statement here.
The position paper, which includes 81 consensus statements, was developed by five international liver societies representing North America, Europe, Asia-Pacific, Latin America, and Africa. It was presented Nov. 7 at The Liver Meeting 2026 in Denver.
According to the paper, ACLF occurs when patients with chronic liver disease experience acute clinical deterioration, widespread inflammation, organ failure, and a high risk of death in the short term.
Co-corresponding author Jasmohan S. Bajaj, MD, MS, of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University and the Richmond VA Medical Center, told GI & Hepatology News that developing the position paper “has greatly streamlined the way I approach patients and has encouraged me that consensus even in these hard topics can be made because we all aim to do the best by our patients.” He added, “The global representation, easy-to-remember measures that rely on liver-related and validated extrahepatic scores, and ability of these data to predict clinically relevant outcomes have improved my ability to communicate this to my colleagues and trainees.”
The consensus defines liver failure as a bilirubin level of at least 5 mg/dL and an international normalized ratio of at least 1.5. Diagnosis also requires advanced chronic liver disease, with at least stage F3 fibrosis, and dysfunction or failure of at least one organ outside the liver.
Under the new criteria, patients without prior decompensation are classified as type A, while those with a history of decompensated cirrhosis are classified as type B.
Disease severity is divided into three grades. Grade 1 involves liver failure and dysfunction of one organ outside the liver. Grade 2 involves liver failure and failure of one additional organ, while grade 3 involves liver failure and failure of at least two additional organs.
The consensus defines organ failure outside the liver as stage 2 or 3 acute kidney injury, grade 3 or 4 hepatic encephalopathy, need for mechanical ventilation for respiratory causes or a PaO2/FiO2 ratio of 225 or lower, and vasopressor use for circulatory failure, excluding use solely to treat hepatorenal syndrome.
The consensus also emphasizes that tracking changes in organ function over time is more useful for predicting patient outcomes than a single assessment.
Consensus development
Working groups from the five societies reviewed published research and rated the strength of the evidence. Adoption of a statement required more than 70% agreement. Following a May 2026 meeting in Barcelona, where the FDA and other attendees raised questions, the groups revised 12 statements, all of which achieved consensus in a second vote.
The final statements cover diagnosis, causes of liver injury, intensive care, liver transplantation, and clinical trial design.
Treatment and transplantation
The panel recommends against corticosteroids for patients with severe alcohol-related hepatitis and grade 3 ACLF because the probability of response, as estimated by the Lille model, is very low. Among patients with two organ failures, about 40% are expected to respond, warranting treatment decisions on a case-by-case basis.
For patients receiving corticosteroids, the consensus recommends assessing the Lille score on days 4 and 7 to identify those who are not responding and limit steroid exposure and infection risk.
The recommendations also emphasize promptly identifying and treating infections and regularly monitoring organ function.
Among patients with higher-grade ACLF awaiting transplantation, 50% to 70% or more may die within 28 days, according to the paper. However, evidence reviewed by the panel suggests that more than 80% of carefully selected patients who undergo timely transplantation survive at least one year.
The consensus recommends evaluating patients with severe ACLF for transplantation as soon as possible and states that a minimum period of alcohol abstinence should not be required before patients are placed on the transplant waiting list. It also calls for assessing the risk of return to alcohol use and recommends offering transplantation only to patients with an expected one-year survival above 75% to 80%. Therapeutic plasma exchange may help stabilize organ function in patients awaiting transplantation, according to the consensus.
Clinical implications and limitations
For critically ill patients, the recommendations favor prognostic scores that assess liver and other organ function over traditional cirrhosis scores. Reassessment three to seven days after intensive care admission can help guide decisions about continuing aggressive organ support and introducing palliative care, according to the consensus.
For future phase 2b and 3 trials, the consensus recommends survival as the primary endpoint, accounting for liver transplantation.
The authors identified evidence gaps. Respiratory support recommendations rely largely on research involving other critically ill patients. Questions remain about which patients benefit from plasma exchange and how it should be administered. Several prognostic scores need broader validation using the new definition, and access to elastography and liver transplantation remains uneven, particularly in resource-limited settings.
Some authors reported European Union or German research funding. Dr. Bajaj’s institution receives research grants from Genfit and Bausch, and other authors reported consulting or speaking fees from companies including Gilead, Grifols, and Roche.
Expert insight
Dr. Bajaj expanded on the paper’s relevance to clinical practice.
How will the new global definition of acute-on-chronic liver failure change how physicians diagnose and assess patients?
Dr. Bajaj: We made several conscious decisions in this consensus to ensure the definitions were globally representative, easy to apply, liver-centric, starting from a background of F3 or higher and cirrhosis, and most importantly benchmarked toward mortality using data collected across global cohorts. This will aid not only specialists, but also clinicians in emergency rooms, critical care, and hospital medicine to diagnose and grade ACLF easily.
What clinical signs should prompt early referral for liver transplantation?
Dr. Bajaj: Depending on whether deceased or living donor liver transplantation is available, the recognition of ACLF grades may help prognosticate the outcome. The ACLF grades 1 and 2 should prompt consideration while grade 3 is clearly a group that needs urgent consideration and referral to a liver transplant center if not available at their current center.
How can physicians use the new recommendations to improve treatment decisions and patient survival?
Dr. Bajaj: The pragmatic definition with benchmarks toward mortality can be used to prognosticate patients, refer them for liver transplant or newer trials in ACLF. These recommendations will harmonize these diagnoses worldwide, standardize therapies and diagnoses, and ensure that forthcoming papers on this topic can be interpreted without differences across regions.
Is there anything else you’d like to say about this work?
Dr. Bajaj: This consensus is unprecedented in scope and breadth across the globe and is a major achievement for all five major global liver societies. The consensus statements are not only related to clinical care, transplant, and critical care, but also set the stage for regulatory approvals, and endpoints for trials for newer therapies and interventions to prevent and treat ACLF.